COMMUNIQUÉS West-GlobeNewswire

-
Assure Holdings to Present at the 8th Annual Gateway Conference on September 4th
21/08/2019 -
SPR Therapeutics’ SPRINT Peripheral Nerve Stimulation System Significantly Reduces Opioid Use in Patients with Low Back Pain, Interim Data Show
21/08/2019 -
Shockwave Medical to Participate in Upcoming Investor Conferences
21/08/2019 -
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
21/08/2019 -
Golden Leaf Holdings to Report Fiscal Second Quarter Earnings
21/08/2019 -
SHINKEI Therapeutics Announces Investigational New Drug Application Submission for MR-201, a Novel Dosage Form for Treatment of Pseudobulbar Affect
21/08/2019 -
Republic of Colombia’s food and drug regulatory agency grants clearance for Biomerica’s colorectal cancer screening test to be sold in Colombia
21/08/2019 -
Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect
21/08/2019 -
Progressive Care Inc. Reports Record Revenue of $3.4 Million for July 2019
21/08/2019 -
Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference
21/08/2019 -
Fear of Rejection is Transplant Patient’s Top Concern
21/08/2019 -
BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights
21/08/2019 -
HempAmericana Launches North American CBD Sales Force Following Successful Inventory Build
21/08/2019 -
CURE Pharmaceutical [OTCQB: CURR] Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms
21/08/2019 -
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development
21/08/2019 -
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
21/08/2019 -
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
21/08/2019 -
YSS Corp. Announces Second Quarter 2019 Results and Operational Update
21/08/2019 -
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
21/08/2019
Pages